Literature DB >> 17497975

Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply?

Universe C Leung1, Phillip Y Wong, Ross H Roberts, Jonathan B Koea.   

Abstract

INTRODUCTION: Polyps of the gall bladder (PLG) are common findings in radiological investigations of the gall bladder and most are benign although carcinoma of the gall bladder can arise in PLG. In the general population PLG less than 1 cm in diameter are thought to have a low risk of malignancy and can be cautiously observed.
METHODS: All patients undergoing surgical resection for gall bladder cancer were entered into a prospective database. Four patients with primary sclerosing cholangitis (PSC) presenting with gall bladder cancer in a PLG are studied.
RESULTS: Four patients (two men; median age 46.5 years, range 37-71 years) presented with PLG and known histories of PSC. All patients were shown to have PLG of size between 7 mm x 8 mm and 25 mm x 14 mm on imaging with no radiological evidence of carcinoma. Tumour markers carcinoembryonic antigen and CA19-9 were within the normal range in all patients. All patients were managed with cholecystectomy. Two patients with T1 tumours remain alive and well at 2 and 4 years post-cholecystectomy. Of the remaining two patients with T2 tumours, one underwent re-resection of the liver bed and portal lymph nodes and remains alive and well at 12 months. The remaining patient developed an abdominal wall recurrence 12 months after cholecystectomy. She has also undergone resection with postoperative radiation therapy and remains well after 12 months of clinical follow up.
CONCLUSION: Gall bladder polyps, which are common and are usually benign in the general population, are often malignant in PSC. Regardless of size, any PLG in a patient with PSC should be considered for cholecystectomy.

Entities:  

Mesh:

Year:  2007        PMID: 17497975     DOI: 10.1111/j.1445-2197.2007.04059.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  9 in total

1.  The value of thioredoxin family proteins and proliferation markers in dysplastic and malignant gallbladders in patients with primary sclerosing cholangitis.

Authors:  Karouk Said; Hans Glaumann; Mikael Björnstedt; Annika Bergquist
Journal:  Dig Dis Sci       Date:  2012-02-28       Impact factor: 3.199

2.  Gallbladder lesions identified on ultrasound. Lessons from the last 10 years.

Authors:  Ioannis T Konstantinidis; Surabhi Bajpai; Avinash R Kambadakone; Kenneth K Tanabe; David L Berger; Hui Zheng; Dushyant V Sahani; Gregory Y Lauwers; Carlos Fernandez-del Castillo; Andrew L Warshaw; Cristina R Ferrone
Journal:  J Gastrointest Surg       Date:  2011-11-23       Impact factor: 3.452

Review 3.  Cancer surveillance in patients with primary sclerosing cholangitis.

Authors:  Nataliya Razumilava; Gregory J Gores; Keith D Lindor
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 4.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

Review 5.  Clinical features and management of primary sclerosing cholangitis.

Authors:  Marina-G Silveira; Keith-D Lindor
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

6.  Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat.

Authors:  Giulia Bonato; Laura Cristoferi; Mario Strazzabosco; Luca Fabris
Journal:  Dig Dis       Date:  2015-12-07       Impact factor: 2.404

7.  Diagnosis and management of gallbladder polyps.

Authors:  Ake Andrén-Sandberg
Journal:  N Am J Med Sci       Date:  2012-05

8.  Rapid progression of primary sclerosing cholangitis complicated with ulcerative colitis.

Authors:  Piotr Pardak; Ewa Walczak; Rafał S Filip
Journal:  Case Rep Gastrointest Med       Date:  2015-01-28

Review 9.  Current practices and future prospects for the management of gallbladder polyps: A topical review.

Authors:  R Stephen McCain; Anna Diamond; Claire Jones; Helen G Coleman
Journal:  World J Gastroenterol       Date:  2018-07-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.